Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B
Sponsor: Gilead Sciences
Listed as NCT01940471, this PHASE3 trial focuses on HBeAg-positive Chronic Hepatitis B and remains completed. Sponsored by Gilead Sciences, it has been updated 21 times since 2013, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
21 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 16 earlier versions
-
Jan 2023 — Nov 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Sep 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Ankara, Turkey (Türkiye) , Arlington, United States , Auckland, New Zealand , Barcelona, Spain , Bialystok, Poland , Bologna, Italy , Boston, United States , Bucharest, Romania , Bursa, Turkey (Türkiye) and 102 more locations